North America Human Microbiome Market

The North America human microbiome market is expected to grow from USD 0.78 billion in 2025 to USD 4.15 billion by 2031 at a strong CAGR of 32.2%.

Key players in the market include Seres Therapeutics, Seed Health, IFF, Pendulum, BioGaia, OptiBiotix, EV Biotech, Ginkgo Bioworks, P&G, and Finch Therapeutics Group. These companies are expanding through partnerships, product launches, acquisitions, and clinical progress. In 2026, Seres Therapeutics received approval for Rebyota in Canada, strengthening its regional presence.

To know about the assumptions considered for the study download the pdf brochure

Seres Therapeutics (US) is one of the leading companies in the North American microbiome market. It develops oral live biotherapeutic products using defined bacterial consortia. Its key product, VOWST, became the first FDA-approved oral microbiome therapeutic in April 2023 to prevent recurrent C. difficile infections. In 2024, Seres invested USD 64.6 million in R&D and narrowed its research focus. The company also transferred full commercialization rights for VOWST to Nestlé Health Science. Seres continues to advance the rest of its pipeline through collaborations with industry and academia.

International Flavors & Fragrances Inc. (IFF) works across nutrition, flavor, biosciences, and microbiome-based ingredients. It possesses strong capabilities in precision fermentation and strain engineering, enabling the large-scale production of next-generation probiotics, including strict anaerobes such as Akkermansia. IFF’s HOWARU probiotic line includes clinically studied strains (HN001, HN019, NCFM, Bi-07, Bl-04) designed for immune health, digestion, stress support, and early-life development. These strains are widely used in supplements, functional foods, and health products. IFF continues to innovate through collaborations in synthetic biology and microbiome-based ingredient development.

Seed Health (US) is an emerging player in the US, specializing in science-backed probiotics and synbiotics. Its products target gut health, immune support, women’s health, pediatric needs, and metabolic wellness. Seed uses rigorous strain characterization, controlled manufacturing, and clinical validation to ensure product efficacy. The company is expanding through direct-to-consumer and retail channels. Its focus on research, partnerships, and consumer education positions it as an essential player in the North American microbiome market.

Market Ranking Summary

The North America Human Microbiome Market is moderately consolidated with significant influence from Seres Therapeutics, IFF, and Seed Health. Seres leads in microbiome therapeutics supported by FDA approvals and a strong clinical pipeline. IFF dominates the supplement and functional nutrition space through its widely used HOWARU strains. Seed Health is growing quickly in the consumer wellness category with clinically validated products. These companies continue to shape market growth through R&D investments, product development, clinical partnerships, and innovative microbiome-based solutions.

Related Reports:

North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com